Recombinant factor IX

ApprovedBiologic

BBaxalta now part of Shire

Recombinant factor IX is one of 67 biologic programs targeting Von Willebrand disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

Hemophilia aActive, not recruiting

Hemophilia BActive, not recruiting

Von Willebrand DiseasePhase 3

Active, not recruiting

Hemophilia aApproved

Active, not recruiting

Hemophilia BPhase 3

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Phase 3

16 2

Recombinant factor IX

BBaxalta now part of Shire

Approved

1 3

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

2 4

Eptacog Alfa

Novo Nordisk

Phase 3

1 5

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

1 6

Valoctocogene Roxaparvovec

BioMarin Pharmaceutical

Phase 3

3 7

Recombinant Factor VIII

Bayer

Phase 3

2 8

Rfviia

Roche

Phase 3

1 9

Marstacimab

Pfizer

Phase 3

1 10

PF-06741086

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemophilia B1 trial

BAX 326 Surgery Study in Hemophilia B Patients

Completed·BBaxalta now part of Shire·Phase 3·NCT01507896·30 enrolled

Hemophilia A1 trial

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Completed·BBaxalta now part of Shire·Phase 4·NCT00357656·85 enrolled

Von Willebrand disease1 trial

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Completed·BBaxalta now part of Shire·Phase 3·NCT01410227·49 enrolled

Treatment1 trial

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Completed·BBaxalta now part of Shire·Phase 3·NCT01757405·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Recombinant factor IX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant factor IX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant factor IX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baxalta now part of Shire company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: BBaxalta now part of Shire

Recombinant factor IX

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemophilia B1 trial

Hemophilia A1 trial

Von Willebrand disease1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News